LLY - Eli Lilly and Co
A pharmaceutical giant riding the GLP-1 wave with blockbuster drugs Mounjaro and Zepbound for diabetes and obesity, transforming it into one of the most valuable companies on earth.
Finlify Score
65.5 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$1129.35
-0.32%
52W Range
$623.78 - $1182.73
Market Cap
$1.0T
-0.3%Compared to previous day
2026 Q1 Revenue
$19.8B
+2.6%Changes from last reporting quarter
2026 Q1 EPS
$8.00
Diluted shares
Analyst Rating
39 analysts in latest ratings feed
RSI
61.6
40-70 moderate
2Y Range Position
90%
-4.5% from high / +81.0% from low
Beta
0.51
Relative to market benchmark
MACD
-0.19
MACD line 41.60 / signal line 41.79
Fundamental Trend
Growth 77.7Financial Health
Quality 82.0Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
WATCH65.5 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $19.8B+2.6% | $19.3B+9.6% | $17.6B+13.1% | $15.6B+22.2% |
| Gross Profit | - | - | - | - |
| Operating Income | - | - | - | - |
| Net Income | $7.4B+11.4% | $6.6B+18.9% | $5.6B-1.4% | $5.7B+105.1% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jun 16, 2026
The Finlify signal for LLY is "WATCH" with a Finlify Score of 67.2 out of 100, indicating a generally favorable outlook supported by strong fundamental and financial quality scores. The data quality is "FULL" with no deductions, suggesting comprehensive data coverage for this assessment.
Technical
The asset's Relative Strength score of 63.7/100 suggests positive price momentum, supported by a 20-day return of 12.5% and a 60-day return of 23.4%. LLY appears to be trading close to its 52-week high, at -2.4% distance, with an RSI(14) of 62.7, which may indicate strong buying interest. However, the Accumulation / Volume score of 37.3/100 suggests that buying pressure may not be as robust as price performance indicates.
Fundamentals
LLY exhibits strong fundamental characteristics, with a Fundamental Trend score of 77.7/100 and a Financial Quality score of 82.0/100, reflecting positive underlying business health as of the latest financial period ending 2026-03-31. The company's earnings recently "BEAT" expectations. However, valuation multiples appear elevated, with a P/E ratio of 52.4x, P/B of 38.3x, and P/S of 16.6x, which may suggest a premium valuation. The asset's Beta of 0.5 indicates lower volatility relative to the broader market, and it offers a Dividend Yield of 0.60%.
Macro Context
In the current macro environment, with CPI YoY at 4.3% and Core PCE YoY at 3.3%, persistent inflation may influence market sentiment, potentially impacting growth-oriented assets. The 10-year Treasury yield at 4.5% and a positive yield spread of 0.4% (10Y-2Y) suggest a normalized interest rate environment, which could be generally supportive, though higher rates might pressure valuations for high-P/E stocks like LLY.
Key Risks
- Elevated valuation multiples, such as a P/E of 52.4x and P/B of 38.3x, may suggest limited upside potential if growth expectations are not met.
- The Accumulation / Volume score of 37.3/100 appears relatively low compared to the strong price performance, which could indicate less conviction behind recent price movements.
- Trading at only -2.4% from its 52-week high with an RSI(14) of 62.7 may suggest the asset is approaching overbought conditions, potentially leading to a short-term pullback.